These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 23444225)

  • 1. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
    Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
    Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing.
    Warzecha CC; Sato TK; Nabet B; Hogenesch JB; Carstens RP
    Mol Cell; 2009 Mar; 33(5):591-601. PubMed ID: 19285943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice.
    Baraniak AP; Chen JR; Garcia-Blanco MA
    Mol Cell Biol; 2006 Feb; 26(4):1209-22. PubMed ID: 16449636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395.
    Sun G; Zhou H; Chen K; Zeng J; Zhang Y; Yan L; Yao W; Hu J; Wang T; Xing J; Xiao K; Wu L; Ye Z; Xu H
    J Exp Clin Cancer Res; 2020 Jun; 39(1):116. PubMed ID: 32560659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative analysis of protein-coding and non-coding RNAs identifies clinically relevant subtypes of clear cell renal cell carcinoma.
    Li Z; Chen Y; Hu S; Zhang J; Wu J; Ren W; Shao N; Ying X
    Oncotarget; 2016 Dec; 7(50):82671-82685. PubMed ID: 27705920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
    Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
    Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTBP1 promotes the progression of hepatocellular carcinoma by enhancing the oncogenic splicing switch of FGFR2.
    Chen YY; Zhang Q; Gui MH; Feng L; Cao PB; Zhou GQ
    Yi Chuan; 2024 Jan; 46(1):46-62. PubMed ID: 38230456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.
    Zhu X; Lee K; Asa SL; Ezzat S
    Am J Pathol; 2007 May; 170(5):1618-28. PubMed ID: 17456767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive proteogenomic characterization of rare kidney tumors.
    Li GX; Chen L; Hsiao Y; Mannan R; Zhang Y; Luo J; Petralia F; Cho H; Hosseini N; Leprevost FDV; Calinawan A; Li Y; Anand S; Dagar A; Geffen Y; Kumar-Sinha C; Chugh S; Le A; Ponce S; Guo S; Zhang C; Schnaubelt M; Al Deen NN; Chen F; Caravan W; Houston A; Hopkins A; Newton CJ; Wang X; Polasky DA; Haynes S; Yu F; Jing X; Chen S; Robles AI; Mesri M; Thiagarajan M; An E; Getz GA; Linehan WM; Hostetter G; Jewell SD; Chan DW; Wang P; Omenn GS; Mehra R; Ricketts CJ; Ding L; Chinnaiyan AM; Cieslik MP; Dhanasekaran SM; Zhang H; Nesvizhskii AI;
    Cell Rep Med; 2024 May; 5(5):101547. PubMed ID: 38703764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma].
    Cai TY; Zhu ZP; Xu CR; Ji X; Lv TD; Guo ZK; Lin J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):628-635. PubMed ID: 35950384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis.
    Cha JY; Lambert QT; Reuther GW; Der CJ
    Mol Cancer Res; 2008 Mar; 6(3):435-45. PubMed ID: 18337450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity.
    Oltean S; Sorg BS; Albrecht T; Bonano VI; Brazas RM; Dewhirst MW; Garcia-Blanco MA
    Proc Natl Acad Sci U S A; 2006 Sep; 103(38):14116-21. PubMed ID: 16963563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
    Hornsby CD; Cohen C; Amin MB; Picken MM; Lawson D; Yin-Goen Q; Young AN
    Arch Pathol Lab Med; 2007 Oct; 131(10):1541-6. PubMed ID: 17922590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkers.
    Gulati S; Martinez P; Joshi T; Birkbak NJ; Santos CR; Rowan AJ; Pickering L; Gore M; Larkin J; Szallasi Z; Bates PA; Swanton C; Gerlinger M
    Eur Urol; 2014 Nov; 66(5):936-48. PubMed ID: 25047176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide analysis of differentially expressed genes and splicing isoforms in clear cell renal cell carcinoma.
    Valletti A; Gigante M; Palumbo O; Carella M; Divella C; Sbisà E; Tullo A; Picardi E; D'Erchia AM; Battaglia M; Gesualdo L; Pesole G; Ranieri E
    PLoS One; 2013; 8(10):e78452. PubMed ID: 24194935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
    Liu J; Liu Z; Liu Q; Li L; Fan X; Wen T; An G
    Oncol Rep; 2018 Oct; 40(4):2023-2035. PubMed ID: 30066941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel biomarkers to distinguish clear cell and non-clear cell renal cell carcinoma using bioinformatics and machine learning.
    Panwoon C; Seubwai W; Thanee M; Sangkhamanon S
    PLoS One; 2024; 19(6):e0305252. PubMed ID: 38857246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes.
    Malouf GG; Su X; Yao H; Gao J; Xiong L; He Q; Compérat E; Couturier J; Molinié V; Escudier B; Camparo P; Doss DJ; Thompson EJ; Khayat D; Wood CG; Yu W; Teh BT; Weinstein J; Tannir NM
    Clin Cancer Res; 2014 Aug; 20(15):4129-40. PubMed ID: 24899691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.
    Amann T; Bataille F; Spruss T; Dettmer K; Wild P; Liedtke C; Mühlbauer M; Kiefer P; Oefner PJ; Trautwein C; Bosserhoff AK; Hellerbrand C
    Am J Pathol; 2010 Mar; 176(3):1433-42. PubMed ID: 20093481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.